RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
I-Mab Biopharma of Shanghai reported the China National Medical Products Administration approved its IND for TJ107 (HyLeukin®), a novel long-acting recombinant human interleukin-7 (rhIL-7). I-Mab in-licensed China rights to the immunotherapy in a $548 million agreement late last year from South Korea’s Genexine. To create the long-term effect, Genexine fuses Interleukin-7 with its own hybrid Fc platform. I-Mab will test HyLeukin in patients with chemotherapy-induced lymphopenia and cancer.
Source: China Biotoday
